JP2020505475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505475A5 JP2020505475A5 JP2019562229A JP2019562229A JP2020505475A5 JP 2020505475 A5 JP2020505475 A5 JP 2020505475A5 JP 2019562229 A JP2019562229 A JP 2019562229A JP 2019562229 A JP2019562229 A JP 2019562229A JP 2020505475 A5 JP2020505475 A5 JP 2020505475A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- item
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 143
- 229920001184 polypeptide Polymers 0.000 claims description 125
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 125
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
- 239000005557 antagonist Substances 0.000 claims description 68
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 43
- 102000037865 fusion proteins Human genes 0.000 claims description 37
- 108020001507 fusion proteins Proteins 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 26
- 108010023082 activin A Proteins 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 13
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 10
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 10
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 10
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 10
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 10
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 10
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 10
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 10
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 10
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 10
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 10
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 108010023079 activin B Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 8
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000021039 metastatic melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 229960002450 ofatumumab Drugs 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 20
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 230000000771 oncological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 157
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 39
- 239000000427 antigen Substances 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 244000052769 pathogen Species 0.000 description 21
- 230000001717 pathogenic effect Effects 0.000 description 20
- 230000028993 immune response Effects 0.000 description 15
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 12
- 230000002708 enhancing effect Effects 0.000 description 10
- 102100034134 Activin receptor type-1B Human genes 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000005924 vaccine-induced immune response Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 3
- 108010079292 betaglycan Proteins 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 125000003473 lipid group Chemical group 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000009120 supportive therapy Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022181719A JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453413P | 2017-02-01 | 2017-02-01 | |
| US62/453,413 | 2017-02-01 | ||
| PCT/US2018/016148 WO2018144542A1 (en) | 2017-02-01 | 2018-01-31 | TGFβ AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022181719A Division JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505475A JP2020505475A (ja) | 2020-02-20 |
| JP2020505475A5 true JP2020505475A5 (enExample) | 2021-03-11 |
| JP7246617B2 JP7246617B2 (ja) | 2023-03-28 |
Family
ID=63041217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562229A Active JP7246617B2 (ja) | 2017-02-01 | 2018-01-31 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
| JP2022181719A Pending JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022181719A Pending JP2023012552A (ja) | 2017-02-01 | 2022-11-14 | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200306340A1 (enExample) |
| EP (1) | EP3576773B1 (enExample) |
| JP (2) | JP7246617B2 (enExample) |
| KR (1) | KR20190115037A (enExample) |
| CN (1) | CN110494155A (enExample) |
| AU (1) | AU2018214979A1 (enExample) |
| CA (1) | CA3051696A1 (enExample) |
| WO (1) | WO2018144542A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP7258021B2 (ja) | 2017-11-09 | 2023-04-14 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体を含む医薬組成物 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| CN112601538B (zh) | 2018-05-09 | 2025-08-19 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| CA3103427A1 (en) * | 2018-06-15 | 2019-12-19 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CN116390940A (zh) * | 2020-09-23 | 2023-07-04 | 海正生物制药有限公司 | Tgfbr2-ecd突变体及包含其的融合蛋白与应用 |
| AU2021376241A1 (en) * | 2020-11-04 | 2023-06-22 | Hq Han | Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| CN117721131A (zh) * | 2023-12-19 | 2024-03-19 | 吉林大学 | 一种重组骨形态发生蛋白突变体的制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1486560A3 (en) * | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| CA2673607A1 (en) * | 2006-12-20 | 2008-09-04 | Novarx | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| WO2008094708A2 (en) * | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI606062B (zh) * | 2007-02-09 | 2017-11-21 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| CN101780272B (zh) * | 2009-12-24 | 2012-01-25 | 湖南农业大学 | 一种含有TGF β1自体疫苗制剂的应用 |
| PL2542590T5 (pl) * | 2010-03-05 | 2020-08-10 | The Johns Hopkins University | Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych |
| LT2714735T (lt) * | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| CN107849114B (zh) * | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| EP3828199B1 (en) * | 2015-04-06 | 2025-10-15 | Acceleron Pharma Inc. | Alk7: actriib heteromultimers and uses thereof |
| EP3307772B1 (en) * | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta 3 specific antibodies and methods and uses thereof |
| US20170240639A1 (en) * | 2016-02-22 | 2017-08-24 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
-
2018
- 2018-01-31 CA CA3051696A patent/CA3051696A1/en active Pending
- 2018-01-31 CN CN201880023489.0A patent/CN110494155A/zh active Pending
- 2018-01-31 US US16/482,869 patent/US20200306340A1/en not_active Abandoned
- 2018-01-31 JP JP2019562229A patent/JP7246617B2/ja active Active
- 2018-01-31 KR KR1020197025689A patent/KR20190115037A/ko not_active Ceased
- 2018-01-31 AU AU2018214979A patent/AU2018214979A1/en not_active Abandoned
- 2018-01-31 WO PCT/US2018/016148 patent/WO2018144542A1/en not_active Ceased
- 2018-01-31 EP EP18747362.4A patent/EP3576773B1/en active Active
-
2022
- 2022-11-14 JP JP2022181719A patent/JP2023012552A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505475A5 (enExample) | ||
| CN112480253B (zh) | 一种抗pd-l1纳米抗体及其衍生物和用途 | |
| AU2019232838B2 (en) | Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage | |
| CN111423512B (zh) | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 | |
| JP2018503380A5 (enExample) | ||
| JP2023552851A (ja) | 二重特異性抗体およびその適用 | |
| WO2019062642A1 (zh) | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 | |
| JP6636066B2 (ja) | ヒトｐ１８５及び血管内皮増殖因子の両方を標的とする抗体及びその適用 | |
| Troiani et al. | Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance | |
| JP6519090B2 (ja) | 血管内皮成長因子融合タンパク質 | |
| JP2019506863A (ja) | Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質 | |
| JP2013507926A (ja) | ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用 | |
| CN101652387A (zh) | Alk1受体和配体拮抗剂及其用途 | |
| JP2021169475A (ja) | 高親和性抗ｖｅｇｆ抗体 | |
| CN102884084A (zh) | 抗her2抗体及组合物 | |
| JP2018501211A5 (enExample) | ||
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| CN114044827A (zh) | 低adcc/cdc功能性单抗及其制备方法与应用 | |
| JP2023531672A (ja) | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 | |
| US20240082394A1 (en) | Combination therapy for the treatment of cancer | |
| CN114616251B (zh) | 靶向PD-1和TGFβ的重组蛋白 | |
| JPWO2022121239A5 (enExample) | ||
| JP6887944B2 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| AU2023336948A1 (en) | Pharmaceutical composition and use thereof |